The future of epigenetic therapy in solid tumours--lessons from the past.

The future of epigenetic therapy in solid tumours--lessons from the past.
复制标题

DOI:
10.1038/nrclinonc.2013.42
复制
发表时间:
2013-05
期刊:
Nature reviews. Clinical oncology
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

针对癌症治疗的表观遗传异常的承诺尚未实现实体瘤,虽然越来越多的证据表明其在血液恶性肿瘤中的价值。事实上,只有在低剂量的表观遗传靶向药物(即组蛋白脱乙酰酶和DNA甲基转移酶抑制剂)下,造血相关肿瘤的真正临床疗效才变得明显。描述来自临床前研究和早期临床试验结果的数据,我们假设在使用低剂量表观遗传调节剂时,肿瘤细胞可以被重新编程,这覆盖了在高剂量下观察到的任何直接细胞毒性和脱靶效应。我们认为,这种药物剂量的优化和调度目前可用的代理可以给这些代理在癌症管理中的突出位置时,单独使用或与其他疗法相结合。如果是这样的话,这些已知药剂的最佳使用也可能为引入靶向表观基因组的其他药剂铺平道路。
The promise of targeting epigenetic abnormalities for cancer therapy has not been realized for solid tumours, although increasing evidence is demonstrating its worth in haematological malignancies. In fact, true clinical efficacy in haematopoietic-related neoplasms has only become evident at low doses of epigenetic-targeting drugs (namely, inhibitors of histone deacetylase and DNA methyltransferases). Describing data from preclinical studies and early clinical trial results, we hypothesize that in using low-dose epigenetic-modulating agents, tumour cells can be reprogrammed, which overrides any immediate cytotoxic and off-target effect observed at high dose. We suggest that such optimization of drug dosing and scheduling of currently available agents could give these agents a prominent place in cancer management—when used alone or in combination with other therapies. If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome.
DOI: 10.1016/j.ccr.2012.03.045
发表时间: 2012-05-15
期刊: Cancer cell
影响因子: 50.3
作者:
De Carvalho DD;Sharma S;You JS;Su SF;Taberlay PC;Kelly TK;Yang X;Liang G;Jones PA
通讯作者: Jones PA
DOI: 10.1158/1535-7163.mct-11-0873
发表时间: 2012-10
影响因子: 5.7
作者:
Cooper SJ;von Roemeling CA;Kang KH;Marlow LA;Grebe SK;Menefee ME;Tun HW;Colon-Otero G;Perez EA;Copland JA
通讯作者: Copland JA
DOI: 10.1101/gr.131169.111
发表时间: 2012-05-01
期刊: GENOME RESEARCH
影响因子: 7
作者:
Easwaran, Hariharan;Johnstone, Sarah E.;Baylin, Stephen B.
通讯作者: Baylin, Stephen B.
DOI: 10.1002/cncr.25701
发表时间: 2011-04-15
期刊: CANCER
影响因子: 6.2
作者:
Fu, Siqing;Hu, Wei;Iyer, Revathy;Kavanagh, John J.;Coleman, Robert L.;Levenback, Charles F.;Sood, Anil K.;Wolf, Judith K.;Gershenson, David M.;Markman, Maurie;Hennessy, Bryan T.;Kurzrock, Razelle;Bast, Robert C., Jr.
通讯作者: Bast, Robert C., Jr.
DOI: 10.1056/nejmoa1013343
发表时间: 2011-06-30
期刊: The New England journal of medicine
影响因子: --
作者:
Bejar R;Stevenson K;Abdel-Wahab O;Galili N;Nilsson B;Garcia-Manero G;Kantarjian H;Raza A;Levine RL;Neuberg D;Ebert BL
通讯作者: Ebert BL